BRIEF-Anika Therapeutics expects to complete supplemental phase III trial of CINGAL in 2018

* Anika announces first patient enrolled in supplemental phase III trial of CINGAL for the treatment of knee pain associated with osteoarthritis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.